Editas Medicine Inc (NAS:EDIT)
$ 1.199 -0.011 (-0.91%) Market Cap: 99.88 Mil Enterprise Value: -126.72 Mil PE Ratio: 0 PB Ratio: 0.57 GF Score: 46/100

Editas Medicine Inc at Barclays Virtual Gene Editing & Gene Therapy Summit Transcript

Nov 16, 2020 / 03:15PM GMT
Release Date Price: $29.06 (-0.58%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Welcome, everyone. Thank you, and welcome. Joining us next presenting company is Editas Medicine. With me, we have Cindy Collins, President and Chief Executive Officer; Charlie Albright, our Chief Scientific Officer; Michelle Robertson, Chief Financial Officer; Mark Mullikin, VP of Finance and Investor Relations. With that, I will hand over to Cindy.

Cynthia L. Collins
Editas Medicine, Inc. - President, CEO & Director

Thank you, Gena. So good morning, everyone. Thank you for joining us here today.

Pushing forward the boundaries of medicine entails risk as well as great progress. This slide tells you all about the risk. At Editas, we strive to make differentiated transformational medicines for diseases of high unmet need. To accomplish this objective, we are pursuing 2 strategic pillars, in vivo CRISPR medicines and ex vivo cell medicines. In our in vivo CRISPR medicine portfolio, we are able to leverage our proprietary smaller Staph. aureus Cas9 enzyme for more efficient and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot